Journal of Clinical Oncology, Vol 15, 2667-2672, Copyright © 1997 by American Society of Clinical Oncology
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
R Pawson, MJ Dyer, R Barge, E Matutes, PD Thornton, E Emmett, JC Kluin-Nelemans, WE Fibbe, R Willemze and D Catovsky
Academic Department of Hematology and Cytogenetics, Royal Marsden Hospital, London, United Kingdom.
PURPOSE: T-prolymphocytic leukemia (T-PLL) is an aggressive malignancy of
mature T cells refractory to conventional chemotherapy, with a median
survival duration of 7.5 months. We report here promising results with the
use of a genetically reshaped human CD52 antibody, CAMPATH-1H. PATIENTS AND
METHODS: Fifteen patients with T-PLL, most of whom had received the purine
analog deoxycoformycin (DCF), were treated with CAMPATH-1H. Results were
compared with those of 25 patients treated with DCF. RESULTS: Major
responses occurred in 11 patients (73%) treated with CAMPATH-1H compared
with 40% with DCF. Complete remissions (CRs) were documented in nine (60%)
of the CAMPATH-1H cases and only three (12%) were obtained with DCF. CRs
with CAMPATH-1H were durable, and re-treatment with the antibody resulted
in second CRs in three relapsed patients. Two of them were successfully
autografted with peripheral-blood and bone marrow stem cells collected
during the first CR. Apart from first-dose reactions, infusions of
CAMPATH-1H were well tolerated. However, two responding patients developed
severe bone marrow aplasia that was fatal in one; the second remained
moderately pancytopenic 21 weeks after stopping CAMPATH-1H therapy. The
cause of this adverse effect is unknown. CONCLUSION: CAMPATH-1H is an
effective agent in T-PLL and represents a significant improvement over
other types of therapy. However, CAMPATH-1H alone is not sufficient for
long- term remissions, and the role of autologous stem-cell transplantation
needs further investigation.
This article has been cited by other articles:
|
|
|
|
 
H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood,
August 15, 2008;
112(4):
1039 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Demko, J. Summers, P. Keegan, and R. Pazdur
FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
Oncologist,
February 1, 2008;
13(2):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al.
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Clin. Cancer Res.,
January 15, 2008;
14(2):
569 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Flynn and J. C. Byrd
Have We Forgotten the Purpose of Phase III Studies?
J. Clin. Oncol.,
December 10, 2007;
25(35):
5553 - 5555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok
Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)
Clin. Cancer Res.,
December 1, 2006;
12(23):
7174 - 7179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Christiansen and A. K. Rajasekaran
Biological impediments to monoclonal antibody-based cancer immunotherapy
Mol. Cancer Ther.,
November 1, 2004;
3(11):
1493 - 1501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Lenihan, A. J. Alencar, D. Yang, R. Kurzrock, M. J. Keating, and M. Duvic
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
Blood,
August 1, 2004;
104(3):
655 - 658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou
Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting
Ann. Onc.,
March 1, 2004;
15(3):
369 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, M. Zhang, C. K. Goldman, J. V. Ravetch, and T. A. Waldmann
Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H
Cancer Res.,
October 1, 2003;
63(19):
6453 - 6457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. S. Buggins, G. J. Mufti, J. Salisbury, J. Codd, N. Westwood, M. Arno, K. Fishlock, A. Pagliuca, and S. Devereux
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
Blood,
August 13, 2002;
100(5):
1715 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, B. Cazin, S. Coutre, R. Birhiray, T. Kovacsovics, W. Langer, B. Leber, T. Maughan, K. Rai, G. Tjonnfjord, et al.
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed
J. Clin. Oncol.,
January 1, 2002;
20(1):
205 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T Wu
Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia
Journal of Oncology Pharmacy Practice,
December 1, 2001;
7(4):
133 - 140.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. E. Dearden, E. Matutes, B. Cazin, G. E. Tjonnfjord, A. Parreira, B. Nomdedeu, P. Leoni, F. J. Clark, D. Radia, S. M. B. Rassam, et al.
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
Blood,
September 15, 2001;
98(6):
1721 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Xu, S. A. Leadon, Y. Yu, C. M. Boyer, K. O’Briant, K. Ward, A. McWatters, X. Zhao, D. S. Bae, K. DeSombre, et al.
Synergistic Interaction between Anti-p185HER-2 Ricin A Chain Immunotoxins and Radionuclide Conjugates for Inhibiting Growth of Ovarian and Breast Cancer Cells That Overexpress HER-2
Clin. Cancer Res.,
August 1, 2000;
6(8):
3334 - 3341.
[Abstract]
[Full Text]
|
|
|
|
